Akili, Inc. (AKLI)
Jul 2, 2024 - AKLI was delisted (reason: acquired by Virtual Therapeutics)
0.433
+0.001 (0.25%)
Inactive · Last trade price on Jul 1, 2024

Akili Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year Ending
TTM Dec '23 Dec '22 Dec '21 Dec '20
Revenue
1.951.680.320.543.94
Revenue Growth (YoY)
426.49%419.50%-39.96%-86.34%-
Cost of Revenue
0.860.820.440.360.42
Gross Profit
1.090.86-0.120.183.52
Selling, General & Admin
39.345.4261.742.6713.54
Research & Development
18.0219.9328.8618.2315.42
Operating Expenses
57.3265.3490.5660.928.96
Operating Income
-56.23-64.49-90.68-60.72-25.44
Interest Expense / Income
2.192.361.480.470.33
Other Expense / Income
-9.93-7.4-84.220.16-0.12
Pretax Income
-48.49-59.44-7.95-61.35-25.65
Income Tax
0.050.050.0200
Net Income
-48.55-59.49-7.96-61.35-25.65
Preferred Dividends
0011.0865.310
Net Income Common
-48.55-59.49-19.04-126.66-25.65
Shares Outstanding (Basic)
79783011
Shares Outstanding (Diluted)
79783011
Shares Change
0.57%161.72%2067.39%19.32%-
EPS (Basic)
-0.61-0.76-0.64-91.88-22.20
EPS (Diluted)
-0.61-0.76-0.64-91.88-22.20
Free Cash Flow
-49.14-58.01-83.56-54.47-24.67
Free Cash Flow Per Share
-0.63-0.74-2.80-39.52-21.35
Gross Margin
56.11%51.19%-36.53%34.01%89.44%
Operating Margin
-2886.60%-3842.97%-28073.37%-11286.06%-645.75%
Profit Margin
-2492.04%-3545.47%-5894.43%-23542.19%-651.08%
Free Cash Flow Margin
-2522.33%-3457.09%-25870.90%-10125.28%-626.22%
EBITDA
-45.35-56.09-5.66-60.6-25.01
EBITDA Margin
-2327.77%-3342.55%-1753.56%-11264.68%-634.98%
Depreciation & Amortization
0.960.990.80.280.3
EBIT
-46.3-57.08-6.46-60.88-25.31
EBIT Margin
-2376.95%-3401.79%-2000.31%-11316.54%-642.60%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).